Canada-based Highland Therapeutics has reported positive results from a Phase I study of a novel formulation of methylphenidate, HLD-200, to treat attention-deficit/hyperactivity disorder (ADHD).

Conducted in collaboration with the Harvard Clinical Research Institute (HCRI) and Massachusetts General Hospital (MGH), the study of HLD-200 was conducted on humans for the first time to examine its pharmacokinetic profile.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

"The third-party market research we have conducted indicates substantial pent-up demand for Highland’s products, which could become first-line therapy in both the adult and pediatric/adolescent patient populations."

The study noted a longer absorption window for HLD-200, when compared with other methylphenidate products available in the market.

In the single-centre, single-dose, open-label trial, 12 patients were enrolled and administered with two methylphenidate HCl modified release and an immediate release methylphenidate HCl marketed formulations subsequent to a washout period between treatments.

The study highlights the class-leading low level of variability with respect to a critical parameter, the time to maximum concentration (Tmax), and a similar low coefficient of variation (CV%) to that of the HLD-100 Phase-1 study.

See Also:

Senior study adviser and medical monitor, MGH paediatric psychopharmacology and adult ADHD clinical and research programmes chief Dr Joseph Biederman said, "The data suggest that Highland has developed a potential new treatment option for ADHD that could consistently deliver the medication so that the symptoms of ADHD can be controlled immediately upon wakening while also providing once-daily coverage."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Highland chief executive officer David Lickrish said the data for both amphetamine and methylphenidate programmes suggest that the drug-delivery technology is a platform technology, applicable to other active ingredients in a range of therapeutic categories.

"The third-party market research we have conducted indicates substantial pent-up demand for Highland’s products, which could become first-line therapy in both the adult and pediatric/adolescent patient populations," Lickrish added.